NEONATAL MEDICATION PROTOCOLS

OSELTAMIVIR
Created by: NCCU
Date for review: Oct 2016

NCCU Clinical Guidelines
KEMH/PMH
Perth, Western Australia

DRUG:	**OSELTAMIVIR**
PRESENTATION:	Capsules: 75mg Oral suspension 6 mg/mL
ACTION & INDICATION:	Antiviral for: Treatment of Influenza A, B, H1N1 (human swine influenza)
DOSE:	**Treatment Dose** <38 weeks 1 mg/kg/dose twice daily for 5 days 38-40 weeks 1.5 mg/kg/dose twice daily for 5 days >40 weeks 3 mg/kg/dose twice daily for 5 days A longer duration of therapy may be considered for patients who remain severely ill after 5 days of treatment.
PREPARATION:	Add 55 mL of water to powder for suspension in the bottle = 6mg/mL If commercial oral suspension not available or not suitable, (see Comments) dose can be prepared by dispersing the contents of one 75mg capsule with 6.25mL of water = 12mg/mL. Allow 2 minutes to disperse.
ADMINISTRATION:	Oral: May be given with or without food. Tolerability may be improved with food To avoid confusion, the supplied Tamiflu® oral syringe should not be used.
ADVERSE EFFECTS:	Generally well tolerated. GI side effects (diarrhoea, vomiting, abdominal pain) Conjunctivitis Transient rise in transaminases Rare: anaphylaxis and severe skin tractions
COMMENTS:	The osmolality of a dispersed capsule is 75 mOsm/kg. The osmolality of the suspension will be greater than this, and is suitable for infants on full feeds only. The reconstituted suspension does NOT require refrigeration and should be discarded after 10 days. Discard any unused dispersed capsule immediately.
REFERENCES:	Neofax 2013 Tamiflu® Product Information WA Department of Health “Operational Directives” OD0202/09, OD0203/09
DATE:	October 2013